ClinicalTrials.gg
CompletedNCT00672919COMPLEMENTUpdated Feb 28, 2012

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

A Phase 4 interventional study of Pioglitazone in Diabetes Mellitus, sponsored by Takeda. Completed at 53 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-28.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
305
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
31st of 122
305 · median 103
Started
2003
with 5 others
Phase 4
57 of 122
4 open now
Registered
37th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 6 that started in 2003, is one of 57 in phase 4, and was the 37th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.

Read the detailed description

Diabetes mellitus is a chronic disease with multiple metabolic defects that result in hyperglycemia arising from inadequate insulin activity. Type 2 diabetes has a genetic predisposition, but lifestyle, physical habits and age play important roles in determining its time of onset and severity. Type 2 diabetes is usually the result of a progression from reduced sensitivity of hepatic (liver) and peripheral-tissue cells to circulating insulin (ie, insulin resistance) to a progressive inability of the body to produce adequate insulin to overcome insulin resistance (ie, insulin deficiency due to beta-cell insufficiency) resulting in impaired glucose tolerance and ultimately overt diabetes. In the United States, an estimated 15.7 million people have diabetes, with type 2 diabetes occurring in approximately 90 to 95% of cases.

Therapeutic agents have been developed to address each of the major functional metabolic defects associated with type 2 diabetes. Recently introduced drugs for diabetes therapy are the thiazolidinedione class. Thiazolidinediones increase glucose utilization, decrease gluconeogenesis and increase glucose disposal through an incompletely understood mechanism but one associated with binding of the drug to receptors known as peroxisomal proliferator-activated receptors.

Thiazolidinediones are peroxisomal proliferator-activated receptor agonists reducing insulin resistance in muscle cells, adipose (fat) tissue, and hepatic cells (inhibiting hepatic gluconeogenesis) with no direct impact on insulin secretion. Thus peroxisomal proliferator-activated receptor agonists improve glycemic control and result in reduced levels of circulating insulin. Peroxisomal proliferator-activated receptors are found in various tissues important for insulin action, with the greatest concentration of these receptors is in adipose tissue.

Pioglitazone is a peroxisomal proliferator-activated receptor agonist developed by Takeda Chemical Industries, Ltd. (Osaka, Japan).

Participation in this study is anticipated to be approximately 20 weeks.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 305 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes mellitus
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study
  • Has been taking a stable dose of rosiglitazone for greater than 90 days prior to screening.
  • Has a triglyceride level greater than 200 mg per dL but less than 1000 mg per dL.
  • Has been taking a stable statin therapy for greater than 90 days prior to screening.
  • Has a glycosylated less than 10.5%.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus.
  • Treated with Gemfibrozil within 90 days of screening.
  • Previous history of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study drug.
  • The subject has an level of greater than 2.5 times the , active liver disease, or jaundice.
  • Male subjects who have serum creatinine greater than 2.0 mg per dL and female subjects with serum creatinine greater than1.8 mg per dL.
  • Unexplained microscopic hematuria greater than plus 1 confirmed by repeat testing.
  • Male subjects who have less than 10.5 g per dL and female subjects who have hemoglobin less than 10.0 g per dL.
  • Significant cardiovascular disease including, but not limited to, Functional (Cardiac) Classification III or IV
  • Currently is participating in another study or has participated in an investigational study within the past 30 days.
  • Any other serious disease or condition that might affect or make it difficult to successfully manage and follow the subject according to the protocol.
  • Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • (eg. prednisone, cortisone, hydrocortisone, dexamethasone) with the exception of a topical glucocorticoid agent.
    • Gemfibrozil
    • Steroid-joint injections.
    • Thiazolidinediones with the exception of the study medication.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    Pioglitazone QD

    (and stable statin therapy)

    Drug: Pioglitazone

Interventions

  • Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.

    Also known as: ACTOS®, AD-4833

07

What researchers measure

Primary outcomes

  1. Change from Baseline in Triglyceride Levels

    Time frame: Weeks 8 and 17 or Final Visit

Secondary outcomes

  1. Change from Baseline in Total Cholesterol

    Time frame: Weeks 8 and 17 or Final Visit

  2. Change from Baseline in direct Low Density Lipoprotein cholesterol

    Time frame: Weeks 8 and 17 or Final Visit

  3. Change from Baseline in High Density Lipoprotein cholesterol

    Time frame: Weeks 8 and 17 or Final Visit

  4. Change from Baseline in apolipoprotein B (apoB)

    Time frame: Weeks 8 and 17 or Final Visit

  5. Change from Baseline in apolipoprotein A1 (apoA1)

    Time frame: Weeks 8 and 17 or Final Visit

  6. Change from Baseline in Free Fatty Acids

    Time frame: Weeks 8 and 17 or Final Visit

  7. Change from Baseline in Lipid Fractionation

    Time frame: Weeks 8 and 17 or Final Visit

  8. Change from Baseline in C-reactive Protein

    Time frame: Weeks 8 and 17 or Final Visit

08

Study locations

53 sites
  • Birmingham,, Alabama, United States
  • Tucson, Arizona, United States
  • Bellflower, California, United States
  • Burlingame, California, United States
  • Fresno,, California, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Pasadena, California, United States
  • Arvada, Colorado, United States
  • Norwalk, Connecticut, United States
  • Waterbury, Connecticut, United States
  • Aventura, Florida, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • N. Miami Beach, Florida, United States
  • Tallahassee, Florida, United States
  • West Palm Beach, Florida, United States
  • Columbus,, Georgia, United States
  • Idaho Falls, Idaho, United States
  • Chicago Heights, Illinois, United States
  • Evansville,, Indiana, United States
  • Des Moines, Iowa, United States
  • Lafayette, Louisiana, United States
  • Fall River, Massachusetts, United States
  • Waltham, Massachusetts, United States
  • Tupelo, Mississippi, United States
  • Chesterfield, Missouri, United States
  • Omaha, Nebraska, United States
  • Staten Island, New York, United States
  • Raleigh, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Centerville, Ohio, United States
  • Dayton, Ohio, United States
  • Medford, Oregon, United States
  • Meadville, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Warwick, Rhode Island, United States
  • Chattanooga, Tennessee, United States
  • Morristown, Tennessee, United States
  • Murfreesboro, Tennessee, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • Houston, Texas, United States
  • Midland, Texas, United States
  • San Antonio, Texas, United States
  • Ogden, Utah, United States
  • Orange, Virginia, United States
  • Virginia Beach,, Virginia, United States
  • Man, West Virginia, United States
  • Wausau, Wisconsin, United States
  • Carolina, Puerto Rico
  • PoncE, Puerto Rico
09

References and documents

Publications

  • Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RC, Demissie S, Fleck PR. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res. 2006 May;3(1):39-44. doi: 10.3132/dvdr.2006.005. Erratum In: Diab Vasc Dis Res. 2006 Sep;3(2):71. PubMed 16784180 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Aug 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2008
First posted
May 6, 2008
Start
Nov 2003
Primary completionActual
Aug 2004
CompletionActual
Aug 2004
Last update
Feb 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00672919
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 6, 2008
Start date
Nov 2003
Primary completion
Aug 2004
Completion
Aug 2004
Last update
Feb 28, 2012

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion